17-AAG及其衍生物治疗肺癌研究进展  

Advances in 17-allylamino-17-demethoxygeldanamycin and its derivatives in lung cancer

作　　者：吴清华(综述)[1] 刘璐(审校)[1] 

机构地区：[1]东南大学临床医学院核技术研究所,南京210009

出　　处：《国际肿瘤学杂志》2009年第8期601-604,共4页Journal of International Oncology

基　　金：基金项目：国家自然科学基金资助项目（30470500）

摘　　要：17-丙烯胺基-17-去甲氧基格尔德霉素（17-AAG）及衍生物17-AAGH2、17-DMAG是热休克蛋白90竞争性抑制剂，能够降解多条信号传导通路关键蛋白，抑制肿瘤细胞生长，促使凋亡。临床Ⅰ-Ⅱ期研究证明，17-AAG及衍生物能够抑制T790M表达类型肺癌细胞，抑制肺癌细胞表皮生长因子受体，协同化疗药物细胞毒性、放射增敏作用。17-allylamino- 17-demethoxygeldanamycin（17-AAG） as well as its derivatives 17-AAGH2 and 17-DMAG are heat shock protein90 inhibitor. It can lead to the depletion of oncogenie client proteins which play key roles in several signal transductions pathways. Cell growth is inhibited and apoptosis is predicated. Clinical phase Ⅰ and phase Ⅱ trials indicate 17-AAG and its derivatives can efficiently inhibit lung cancer cells expressing T790M and epidermal growth ＇factor, coordinate with chemotherapeutics cytotoxicity and increase radiosensitizing effect.

关 键 词：肿瘤 17-丙烯胺基-17-去甲氧基格尔德霉素 药物疗法 

分 类 号：R730.54[医药卫生—肿瘤] R734.2[医药卫生—临床医学]